about
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective ...
Read More
0.98
0.01
(1.03%)
25,307.7
XNAS Volume
XNAS 17 Jul, 2026 12:29 PM (EDT)
Not Eligible
Expensive Valuation
Technically Neutral
MEI Pharma Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..